Four- versus two-point balloon dacryoplasty for blocked tear ducts
Comparative Outcomes of Four Versus Two Balloon Inflation Points in Dacryoplasty for Primary Acquired Nasolacrimal Duct Obstruction
This will see if using four inflation points instead of two during balloon dacryoplasty helps people with primary acquired nasolacrimal duct obstruction get better tear drainage.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT07225244 on ClinicalTrials.gov |
What this trial studies
Patients with primary acquired nasolacrimal duct obstruction will undergo balloon dacryoplasty using the LacriCATH® device and will be assigned to either a two-point or four-point inflation protocol. The procedures dilate the nasolacrimal duct at specified inflation points to restore tear drainage. Outcomes such as symptom relief, duct patency, and procedure-related complications will be tracked over follow-up visits. The comparison aims to determine which inflation approach yields better functional outcomes and fewer repeat procedures.
Who should consider this trial
Good fit: Ideal candidates are people diagnosed with primary acquired nasolacrimal duct obstruction who have not had prior lacrimal procedures and do not have the listed exclusion conditions.
Not a fit: Patients who are pregnant or who have prior lacrimal surgery, upper lacrimal drainage obstruction, punctal stenosis, active dacryocystitis, dacryolithiasis, traumatic obstruction, or a lacrimal mass are unlikely to be eligible or to receive benefit from this procedure.
Why it matters
Potential benefit: If successful, the preferred inflation approach could improve tear drainage and reduce the need for repeat or more invasive lacrimal surgery.
How similar studies have performed: Balloon dacryoplasty is an established technique for nasolacrimal duct obstruction, but head-to-head comparisons of two- versus four-point inflation are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with primary acquired nasolacrimal duct obstruction (PANDO) Exclusion Criteria: * Patients who are pregnant, with previous lacrimal procedure, upper lacrimal drainage obstruction, punctal stenosis, active dacryocystitis, dacryolithiasis, traumatic obstruction or lacrimal mass
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Yi-Hsuan Wei, PhD — National Taiwan University Hospital
- Study coordinator: Yi-Hsuan Wei, PhD
- Email: wn0069@yahoo.com.tw
- Phone: +886-972653324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.